ArticleInternational journal of particle therapy2026
Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma.
Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Classical Hodgkin lymphoma (cHL) is associated with favorable prognosis and high overall survival (OS). Consolidative proton therapy (cPT) represents a modality recommended for young patients due to its reduction in exit dose, with a goal to minimize late effects. We present outcomes of pediatric patients with cHL receiving cPT at initial diagnosis or relapse/refractory (R/R) disease. Materials and Methods: From 10/2007 to 12/2022, 74 patients between the ages of 6 and 22 with cHL treated with cPT after systemic therapy (ST) were included. Risk groups were classified by ST into low, intermediate, and high risk. Involved-site radiotherapy was used for most patients (90%). OS and relapse-free survival (RFS) were estimated using the Kaplan-Meier method; crude cumulative incidence estimates were used to describe recurrence patterns. Results: Median follow-up was 5.5 years (30% > 8 years). Sixty-one (82.4%) patients were treated at initial diagnosis, and 13 (17.6%) received cPT for R/R disease. Median age at diagnosis was 16 years (range, 6.3-21.7), with most being female (58.1%), nodular sclerosing subtype (82.4%), and bulky disease (78.4%). 10-year OS was 96% overall (97% initial, 92% R/R); 10-year RFS was 84% overall (82% initial, 92% R/R). 10-year RFS was 100%, 82%, and 72% for low, intermediate, and high-risk groups. Of the 61 patients treated for initial diagnosis, 8 experienced relapse, with 4 (6.6%) out-of-field & in-field, 3 (4.9%) out-of-field, and 1 (1.6%) in-field. Of the 13 patients treated for R/R disease, 1 experienced an out-of-field recurrence. One patient developed papillary thyroid carcinoma 11.9 years post-cPT (in-field); no other grade 3+ radiation-related late toxicities were observed. Conclusion: cPT is an effective and well-tolerated treatment for young patients with cHL, demonstrating excellent 10-year OS and RFS, even for those treated at relapse. These findings support cPT as a treatment modality, warranting further studies to assess long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.